Astrocytes and Adenosine A2A Receptors: Active Players in Alzheimer’s Disease

Cátia R. Lopes¹, Rodrigo A. Cunha¹,² and Paula Agostinho¹,²*

¹ Center for Neuroscience and Cell Biology, Coimbra, Portugal, ² Faculty of Medicine, University of Coimbra, Coimbra, Portugal

Astrocytes, through their numerous processes, establish a bidirectional communication with neurons that is crucial to regulate synaptic plasticity, the purported neurophysiological basis of memory. This evidence contributed to change the classic “neurocentric” view of Alzheimer’s disease (AD), being astrocytes increasingly considered a key player in this neurodegenerative disease. AD, the most common form of dementia in the elderly, is characterized by a deterioration of memory and of other cognitive functions. Although, early cognitive deficits have been associated with synaptic loss and dysfunction caused by amyloid-β peptides (Aβ), accumulating evidences support a role of astrocytes in AD. Astrocyte atrophy and reactivity occurring at early and later stages of AD, respectively, involve morphological alterations that translate into functional changes. However, the main signals responsible for astrocytic alterations in AD and their impact on synaptic function remain to be defined. One possible candidate is adenosine, which can be formed upon extracellular catabolism of ATP released by astrocytes. Adenosine can act as a homeostatic modulator and also as a neuromodulator at the synaptic level, through the activation of adenosine receptors, mainly of A1R and A2A R subtypes. These receptors are also present in astrocytes, being particularly relevant in pathological conditions, to control the morphofunctional responses of astrocytes. Here, we will focus on the role of A2A R, since they are particularly associated with neurodegeneration and also with memory processes. Furthermore, A2A R levels are increased in the AD brain, namely in astrocytes where they can control key astrocytic functions. Thus, unveiling the role of A2A R in astrocytes function might shed light on novel therapeutic strategies for AD.

Keywords: astrocyte reactivity, amyloid-β protein, synaptic plasticity, cognitive deficits, adenosine A2A receptors, Alzheimer’s disease

ADENOSINE SIGNALING AND ASTROCYTE-NEURON COMMUNICATION

One pathway underlying astrocyte-neuron interactions in CNS is the purinergic signaling, mainly operated by ATP and adenosine that constitute two superimposed signaling systems (Agostinho et al., 2020). ATP released by astrocytes, a subtype of glial cells, is a significant source of adenosine in the brain, being the extracellular adenosine levels regulated by a set of...
ectonucleotidases, in particular by astroglial ecto-5′-nucleotidase (CD73), which is the last and rate-limiting step in the extracellular formation of ATP-derived adenosine (Brisevac et al., 2015). Moreover, adenosine can also be released directly via equilibriative nucleoside transporters (ENT), such as ENT-1 and ENT-2, being the intracellular levels of this nucleoside controlled by the activity of adenosine kinase (ADK), which is mainly expressed in astrocytes and metabolize the conversion of adenosine into AMP (Boison et al., 2010). Adenosine is considered both a neuromodulator and a stress signal, and its functions are mediated by four subtypes of adenosine receptors: A_1R, A_2AR, A_2BR, and A_3R, which are G-protein-coupled receptors, each with a unique pharmacological profile. These metabotropic receptors can recruit different enzymatic activities and/or changes of ion channels function to mediate modulatory actions, with A_1R and A_2R being considered inhibitory and A_2AR and A_3R as facilitatory (reviewed in Cunha, 2016, 2019; Agostinho et al., 2020). Briefly, the activation of A_1R and A_3R, through the action of Gi proteins, inhibits adenylyl cyclase (AC) activity and leads to increased activity of phospholipase C that further triggers its downstream signaling pathways, whereas A_2AR and A_2BR activation, through Gs proteins instigation, increases the production of cAMP to activate protein kinase A (PKA) signaling pathways (Jacobson and Gao, 2006; Cunha, 2016; Agostinho et al., 2020).

Adenosine’s effects in the brain are mostly mediated by A_1R and A_2AR, which prime role is the modulation of synaptic activity, interfering with information transmission within neuronal circuits (reviewed in Fredholm et al., 2005; Cunha et al., 2008; Agostinho et al., 2020). Both A_1R and A_2AR are mostly located in synapses in particular in excitatory (glutamatergic) synapses, although they are also present in gamma-aminobutyric acid (GABA)ergic, cholinergic, dopaminergic, serotonergic, or noradrenergic synapses (reviewed in Cunha, 2016). In excitatory synapses, adenosine under basal conditions can inhibit synaptic transmission via A_1R-mediated activity mainly located in presynaptic terminals (Rebola et al., 2003, 2005). In contrast, A_2AR are only recruited upon higher frequencies of nerve stimulation, triggering plastic changes of synaptic efficiency that enhance glutamate release as well as N-methyl-D-aspartate receptor (NMDAR) activation (Rebola et al., 2008), in order to facilitate synaptic plasticity (reviewed in Cunha, 2016). Synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD), is considered the neurophysiological basis of memory (Martin et al., 2000; Neves et al., 2008). Accordingly, a study using optogenetic tools showed that A_2AR activation, through a phospho-CREB signaling in the hippocampus is sufficient to impair memory function (Li et al., 2015). Moreover, there is evidence supporting a correlation between the adenosine sources and the type of adenosine receptors that are activated, insofar as it was described that A_1R are mainly activated by the tonus of adenosine, formed from the catabolism of ATP released from astrocytes (Pascual et al., 2005) and by postsynaptic adenosine efflux (Lovatt et al., 2012), whereas adenosine derived from synaptically-released ATP, due to CD73 action, mainly activates neuronal, mainly postsynaptic, A_2AR (Cunha et al., 1995; Rebola et al., 2008; Augusto et al., 2013; Carmo et al., 2019; Gonçalves et al., 2019).

Adenosine can also act as an astrocytic modulator, regulating astrocytic metabolism (Lemos et al., 2015), Ca^{2+} waves (Kawamura and Kawamura, 2011; Kanno and Nishizaki, 2012), and neurotransmitter uptake ability (Nishizaki et al., 2002; Cristóvão-Ferreira et al., 2013; Matos et al., 2013). In relation to adenosine signaling in astrocytes, it has been documented that all the different subtypes of adenosine receptors are present in astrocytes, although A_1R and A_2AR have been the most studied (Daré et al., 2007; Boison et al., 2010; Agostinho et al., 2020). Under physiological conditions, the role of adenosine signaling in astrocytes is mostly hypothetical, since it is based on the effects of A_1R and A_2AR in cultured astrocytes; additionally, the role of these receptors in pathological conditions, controlling the morpho-functional changes of reactive astrocytes, seems to be better supported by experimentation, although still far from being established. Among the functions known until now, A_1R in astrocytes mediate an immunosuppressive effect, whereas astrocytic A_2AR can trigger transcriptional deregulation (Paiva et al., 2019) and mediate astrocyte reactivity (Brambilla et al., 2003; Ke et al., 2009), control glutamate release and consequently synaptic transmission (Nishizaki et al., 2002; Cervetto et al., 2017), regulate glutamate uptake by controlling the levels of glutamate transporters and the activity of Na^{+}/K^{+}-ATPase (Nishizaki et al., 2002; Matos et al., 2013). Moreover, it was shown that astrocytic A_2AR and Gs-coupled signaling regulate memory consolidation in mice (Orr et al., 2015). Altogether, these findings highlight the relevant role of astrocytic A_2AR in regulating synaptic plasticity and memory, suggesting that A_2AR in astrocytes might also be a good candidate to normalize memory in case of pathology associated with cognitive deficits, such as in Alzheimer’s disease (AD).

**ASTROCYTES’ ROLE IN ALZHEIMER’S DISEASE**

In the last years, the neurocentric view of AD, which considers neurons as the major players in this neurodegenerative process, has been challenged due to increasing evidences supporting a role of astrocytes in this age-related disease. Although the pathological potential of astrocytes in AD was first recognized in 1910 by Alois Alzheimer, who described the presence of glial cells in close association with dying neurons and reported that glial cells made part of senile plaques (reviewed in Serrano-Pozo et al., 2011; Rodríguez-Arellano et al., 2016), the role of astrocytes in AD pathology has been underexplored. Alzheimer’s disease pathology is associated with an abnormal production of amyloid-beta (A\(\beta\)) peptides that accumulate extracellularly over time, as amyloid plaques. A\(\beta\) peptides are generated through the sequential proteolytic processing of amyloid-beta precursor protein (A\(\beta\)PP) by \(\beta\)-secretase (BACE1) and \(\gamma\)-secretase. Other neuropathological features of AD are the intracellular formation of intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein, together with synaptic dysfunction and loss that progress to neuronal...
Astrocytes and $A_\beta$R in AD

death (Haass and Selkoe, 2007; Selkoe and Hardy, 2016). Several studies have shown that in early AD, corresponding to the first symptoms of cognitive deficits, soluble $A_\beta$ oligomers trigger an extensive proliferation of astrocytes with a reactive phenotype. Reactive astrocytes, besides functional changes, exhibit alterations of their morphology that encompass a hypertrophy of the cell soma and the shortening and/or thickening of astrocytic processes, as well as the upregulation of several astrocytic structural proteins, such as glial fibrillary acidic protein (GFAP), or cell signaling proteins, like S100β (Ceyzériat et al., 2018; Escartin et al., 2021). Astrocyte reactivity usually persists and aggravates over time and parallels $A_\beta$ deposition, being common to observe reactive astrocytes surrounding amyloid plaques in the hippocampus of AD mouse models (Olabarria et al., 2010), as well as in human AD brains (Kashon et al., 2004). Astrogliosis in vivo can be assessed by positron-emission tomography detection of $^{11}$C-deuterium-L-deprenyl ($^{11}$C-DED); deprenyl is a selective inhibitor of monoaminooxidase-B (MAO-B) localized in astrocytes, and an increase in the $^{11}$C-DED signal reflects astrocyte hypertrophy (Fowler et al., 1997; Verkhratsky et al., 2019). On the other hand, the astrocytes located away from amyloid plaques are usually atrophic (Rodríguez et al., 2009; Olabarria et al., 2010). Astrocyte atrophy is detected in several AD mice models as well in in postmortem tissues of patients with advanced (Braak V–VI) stages of AD (see review, Verkhratsky et al., 2019), corresponding to a reduction of astrocytes territories with a decrease in coverage of synaptic contacts and other neuronal structures, and is accompanied by a loss of astrocyte function. These morphofunctional astrocyte changes can also lead to early cognitive deficits through dwindling neuronal support and synaptic dysfunction (Verkhratsky et al., 2019).

Studies performed in mouse models of AD have provided important information about the astrocytic alterations along AD progression. A reduction of volume and surface area of astrocytes, and a decrease in their processes, corresponding to a process of astrodegeneration, has been observed in AD mouse models. Triple transgenic AD mice, 3×TgAD, exhibit astrodegeneration before $A_\beta$ deposition in the medial prefrontal cortex, entorhinal cortex, and hippocampus (Yeh et al., 2011; Kulijewicz-Nawrot et al., 2012; Rodríguez et al., 2014). Astrocyte atrophy was also reported in the hippocampus of other transgenic AD (PDAPP) mouse model at early phases, before formation of amyloid plaques (Beaquis et al., 2014). In contrast, at later stages of AD, the presence of $A_\beta$ deposits triggers a secondary astrogial response, corresponding to a robust reactive astrogliosis in areas surrounding the amyloid plaques (Olabarria et al., 2010; Rodríguez-Arellano et al., 2016; Verkhratsky et al., 2016). This prompts the hypothesis that both this distal atrophy of astrocytes and the proximal astrogial reactivity contribute to the development of AD pathology.

Although, astrogliosis was long considered a broad secondary reaction to pathological conditions, reactive astrocytes can cause harmful effects to other brain cells, either as a consequence of loss of their normal homeostatic functions or due to a gain of toxic functions, linked to a decreased capacity of these cells to remove pathogens and amyloid proteins, in particular $A_\beta$, or to phagocyte dystrophic synapses and cell debris (Barreto et al., 2011; Rodríguez-Arellano et al., 2016; Garwood et al., 2017). There is evidence that reactive astrocytes contribute to amyloid plaque formation, and consequently AD pathology, by different mechanisms, including: (i) hampered phagocytic capacity that is mediated by actin-regulated phagocytosis and/or by several membrane receptors (e.g., lipoprotein receptor-related ligand 1, receptor for advanced glycation end products (RAGE), scavenger receptors); (ii) reduced capacity to degrade the internalized $A_\beta$, which involves the production of proteases, such as neprilysin, insulin-degrading enzyme, and enzymes of the ubiquitin-proteasome system (reviewed in Wyss-Coray et al., 2003; Miners et al., 2008; Ries and Sastre, 2016; Rodríguez-Arellano et al., 2016); and (iii) increased $A_\beta$ production by astrocytes due to BACE1 upregulation and, subsequent, amyloidogenic processing of $A_\beta$PP triggered by proinflammatory conditions, mainly by IL-1β and TNF-α (Blasko et al., 2000; Sastre et al., 2003; Zhao et al., 2011). Although it was reported that reactive astrocytes produced $A_\beta$ in less quantity than neurons, astrocytes mostly produce N-truncated $A_\beta$ species, which are highly prone to aggregation and more toxic than the species produced by neurons (Oberstein et al., 2015; Frost and Li, 2017). Besides having a key role in amyloid pathology, reactive astrocytes can also participate in tau pathology (reviewed in Kovacs, 2020). A recent study reported that hippocampal astrocytes in the dentate gyrus of AD patients exhibit hyperphosphorylated tau, and this abnormal tau impairs Ca$^{2+}$ oscillation and mitochondria motility, distribution, and function in astrocytes, contributing also to reduce: (i) adult neurogenesis; (ii) parvalbumin-expressing neurons; (iii) inhibitory synapses; and (iv) hilar gamma oscillations, which were accompanied by a weakened spatial memory performance (Richetin et al., 2020). Remarkably, since the presence of tau is not detectable in astrocytes under physiological conditions, the origin of this protein in astrocytes in AD-like conditions has been speculated, being proposed that during AD progression, tau translation might occur from mRNA present in astrocytes and astrocytic uptake of extracellular tau, released in the extracellular fluid by neurons, as well as intercellular propagation of tau through exosomes (see Richetin et al., 2020, and references within). In agreement, it was reported that astrocyte reactivity correlates with NFT density in the brains of AD patients (Overymyer et al., 2000; Gallardo and Holtzman, 2019). These findings contribute to sustain that astrogliosis is more directly associated with NFT, and hyperphosphorylated tau, since reactive astrocyte responses increase linearly with NFT burden and distribution, but not with amyloid pathology that tends to reach a plateau (Ingelsson et al., 2004; Serrano-Pozo et al., 2011).

Since the 1990s, several studies pointed out that astrocytes enwrap synaptic terminals and exchange information with them, responding to synaptic activity and regulating synaptic transmission (Parpura et al., 1994; Araque et al., 1999; Halassa et al., 2007; Covelo and Araque, 2016). Thus, astrocyte reactivity, due to $A_\beta$ accumulation and tau dyshomeostasis, may compromise synaptic plasticity and consequently memory. Accordingly, immunohistochemistry studies, assessing GFAP or S100β upregulation and distribution in AD patient's brain,
reported that the degree of astrogliosis is correlated with cognitive decline (Beach and McGeer, 1988; Mrak et al., 1996; Kashon et al., 2004). Studies performed in cultured astrocytes exposed to Aβ peptides showed that these cells became reactive and had a decreased glutamate uptake capacity, due to a downregulation of glutamate transporters, mainly of GLT-1 (Matos et al., 2012b; Zumkehr et al., 2015), being also shown that Aβ42 peptide promotes GLT-1 internalization (Scimemi et al., 2013). These alterations could contribute not only to excitotoxicity but also to impair synaptic plasticity occurring in AD conditions. Accordingly, it was reported that genetic reduction of GLT-1 levels accelerates the onset of cognitive deficit in a double (AβPPSwe/PS1ΔE9) transgenic AD mouse model (Mookherjee et al., 2011), whereas the pharmacological upregulation of GLT-1 ameliorates the pathological tau accumulation, restores synaptic proteins and rescues cognitive decline, with minimal effects on Aβ pathology, in 3xTgAD mice (Zumkehr et al., 2015).

Moreover, Aβ accumulation causes an increased astrocytic excitability, mediated by sporadic Ca2+ signals that spread over to other astrocytes in the form of Ca2+ waves, which were shown to impact on synaptic transmission (Kuchibhotla et al., 2009). The hyperactive Ca2+ signaling might trigger an aberrant release of gliotransmitters, mainly through exocytosis involving the fusion of SNARE proteins of vesicles with the plasma membrane (Araque et al., 1999; Genoud et al., 2006). These alterations in astrocyte excitability and in gliotransmitters release (e.g., ATP, glutamate, D-serine) sustain the possibility of an abnormal metabolism, i.e., the regulation of synaptic plasticity by astrocytes, which might underlie the cognitive deficits observed in most mouse models of AD (Jones, 2015). The increased levels of glutamate and of Aβ oligomers, occurring in early AD phases, affect NMDAR subunits, NR2A and NR2B, which are crucial for synaptic plasticity, being the increased NR2B levels particularly associated with LTP inhibition and metaplasticity inversion in hippocampal slices of a transgenic AD mouse model (AβPP23) with impaired spatial working memory (Balducci et al., 2010). Moreover, soluble Aβ oligomers can engage the astrocytic α7 nicotinic acetylcholine receptors to induce glutamate release from astrocytes that in turn activate extrasynaptic NMDAR in neurons, causing a reduction in miniature excitatory postsynaptic currents (Talantova et al., 2013). In line with these findings, it is believed that the beneficial role of memantine (an NMDAR antagonist), in patients with moderate to severe AD, is mainly mediated through the blockade of extrasynaptic NMDAR activated by excess glutamate (Reisberg et al., 2003). GABA is the major inhibitory transmitter in the adult mammalian brain, and AD patients have increased GABA levels in their cerebrospinal fluid (Samakhashvili et al., 2011) and antagonists of GABA_A receptors improve hippocampal LTP and memory in an AD (APP/PS1) mouse model (Yoshii et al., 2008). In line with these findings, it was reported that hippocampal reactive astrocytes of different AD mouse models (APP/PS1 and 5xFAD) excessively produce GABA and release GABA abundantly through bestrophin 1 (Best1), a channel that in non-reactive astrocytes mediates the release of glutamate (Jo et al., 2014). Moreover, these authors also showed that the abnormal release of GABA by reactive astrocytes reduces the spike probability of granule cells by acting on presynaptic GABA receptors, leading to an impairment of synaptic plasticity and memory in AD mouse models (Jo et al., 2014). Another study also reported that in human AD brains, hippocampal astrocytes have a higher GABA content, and that 5xFAD mice modeling AD have astrocytes also with higher GABA levels and release through astrocyte-specific GABA transporters, GAT3/4 (Wu et al., 2014).

In conclusion, astrocytes support neuronal function, in particular synaptic plasticity, in many ways, and it is plausible that the dysfunction of these glial cells contributes to cognitive deficits associated with AD. In the last years, most of the therapies developed for AD were directed to avoid Aβ formation and accumulation or to normalize synaptic plasticity, as, for example, by inhibiting acetylcholinesterase to normalize acetylcholine levels in the synaptic cleft and by NMDAR antagonism. These strategies have been shown to be little effective, thus there is a need to find novel targets to delay the onset of synaptic and memory deficits in AD (Mangialasche et al., 2010; Morsy and Trippier, 2019).

A possible valid target for AD management is astrocytes, more precisely the manipulation of their functions, and a promising candidate to interfere with the ability of astrocytes to control synaptic function and memory is adenosine receptors, in particular adenosine A2A_R. This stems from observations that: (i) A2A_R are located in astrocytes, where they critically control Na+²/K+²-ATPase (Matos et al., 2012b, 2013), the main energizing system to sustain membrane-dependent processes in astrocytes; (ii) astrocytic A2A_R control glutamate uptake by GLT-1, a process de-regulated in an AD mouse model (Matos et al., 2013); and (iii) astrocytic A2A_R are upregulated in AD animal models and patients (Matos et al., 2015, 2012b; Orr et al., 2015). This is of particular importance in view of the convergence of epidemiological and animal studies showing that caffeine intake is inversely correlated with memory deterioration in aging and in AD, an effect mimicked by the selective A2A_R blockade (Cunha and Agostinho, 2010; Agostinho et al., 2020). Noteworthy, our group showed that the pharmacological activation of A2A_R (Pagnusatt et al., 2015) or the optogenetic activation of neuronal A2A_R intracellular signaling in the hippocampus is actually sufficient to impair memory (Li et al., 2015), and these receptors in astrocytes were also shown to regulate memory processes, since the genetic ablation of astrocytic A2A_R enhances memory performance of aged mice modeling AD (Orr et al., 2015).

ADENOSINE A2A_R SIGNALING IN AD: WHAT IS THE ROLE OF ASTROCYTIC A2A_R?

A2A_R signaling, besides having a discrete role in normal brain function, is mainly able to modulate the development or progression of several brain diseases, including AD (Gomes et al., 2011; Cunha, 2016; Franco and Navarro, 2018). Accordingly, the antagonism of A2A_R has been shown to confer neuroprotection in several injurious and pathological brain conditions and can recover memory deficits in animal models of AD, which prompts A2A_R as a therapeutic target for this disease.
The neuroprotective effect of A<sub>2A</sub>R blockade against different brain pathologies, is mimicked by caffeine (Arendash et al., 2006; Dall'Igna et al., 2007; Canas et al., 2009; Laurent et al., 2016; Viana da Silva et al., 2016; Silva et al., 2018). The regular consumption of caffeine/coffee, a non-selective adenosine receptor antagonist that at dose usually consumed by humans (around 200–300 mg caffeine or 3–5 cups of coffee/day) acts particularly as an A<sub>2A</sub>R antagonist (Fredholm et al., 2005), is inversely correlated with the incidence of AD and later dementia in humans (Maia and de Mendonça, 2002; Eskelinen et al., 2009), and is also protective against cognitive decline in AD mouse models (Arendash et al., 2006; Dall'Igna et al., 2007; Cao et al., 2009; Han et al., 2013; Chen, 2014; Laurent et al., 2014). Curiously, it was also reported that caffeine enhances the consolidation of long-term memories in humans, 24 h after a one-dose (200 mg) administration (Borota et al., 2014). Moreover, our group demonstrated that in rodent AD models, consisting in the intracerebroventricular Aβ injection, both caffeine and the selective A<sub>2A</sub>R antagonist SCH58261 prevent Aβ-induced cognitive impairments and synaptotoxicity (Dall'Igna et al., 2007; Cunha et al., 2008; Canas et al., 2009). A similar protective effect of the A<sub>2A</sub>R antagonist SCH58261 was also observed in AD transgenic (3xTgAD and APP/PS1) mouse models (Viana da Silva et al., 2016; Silva et al., 2018). These data were complemented with studies in rat primary-cultured neurons where it was observed that the pharmacological A<sub>2A</sub>R blockade attenuates Aβ-induced neuronal death through a reduction in A<sub>2A</sub>R-mediated p38 mitogen-activated protein kinase (MAPK) activation and preservation of hippocampal synaptosome function (Canas et al., 2009).

All these findings reporting that the blockade of A<sub>2A</sub>R prevents synaptic dysfunction and cognitive deficits, mainly memory loss, in conditions of AD, support that the modulation of synaptic function may constitute an interesting strategy to improve memory dysfunction related to neurodegenerative processes (Coleman et al., 2004; Wishart et al., 2006; Canas et al., 2018).

In accordance with the putative role of A<sub>2A</sub>R as a therapeutic target in AD, it was reported that A<sub>2A</sub>R levels are increased in the hippocampus of AD patients, in astroglial cells (Angulo et al., 2003; Orr et al., 2015), and also in the frontal cortex of AD (Albasanz et al., 2008). A recent study showed that aging also caused a significant upsurge of A<sub>2A</sub>R in hippocampal neurons of aged humans, a phenotype aggravated in AD patients (Temido-Ferreira et al., 2020). Regarding A<sub>1</sub>R, there are evidences from positron emission tomography (PET) studies that their levels are decreased in the hippocampus of AD patients (Fukumitsu et al., 2008), whereas increased levels of A<sub>1</sub>R were detected in postmortem AD frontal cortex (Albasanz et al., 2008) and in degenerating neurons with neurofibrillary tangles and in dystrophic neurites of senile plaques (Angulo et al., 2003). Likewise, in AD mice and in aged mice, a cortical and hippocampal upsurge of A<sub>2A</sub>R was reported mainly in glutamatergic synapses (Diógenes et al., 2007; Canas et al., 2009; Costenla et al., 2011), and recently, A<sub>2A</sub>R overexpression was reported to be sufficient to drive age-like memory impairments in young rats and to uncover a hippocampal LTD-to-LTP shift, which is a signature of memory impairment (Temido-Ferreira et al., 2020). Furthermore, the activation of A<sub>2A</sub>R in endothelial cells was shown to increase blood–brain barrier (BBB) permeability in mice, facilitating the penetration of macromolecules into the brain, such as proinflammatory and neurotoxic factors, which might contribute to AD pathology (Carman et al., 2011). Curiously, a gene-based association study reported that the gene encoding A<sub>2A</sub>R (ADORA2A) is associated with hippocampal volume in humans, being its minor allele, rs9608282, related with larger hippocampal volumes and better memory (Horgusluoglu-Moloch et al., 2017).

Although the above-described findings reinforce a link between A<sub>2A</sub>R and cognitive deficits associated with AD, the impact of astrocytic A<sub>2A</sub>R in AD-associated cognitive deficits has surprisingly been underexplored. In the brain of AD patients, it was reported that A<sub>2A</sub>R levels are increased in astrocytes but not in microglia (Orr et al., 2015). Moreover, cultured astrocytes exposed to Aβ1–42 also exhibited an upregulation of A<sub>2A</sub>R, which is related with a reduced capacity of astrocytes to uptake glutamate (Matos et al., 2012b) that can trigger excitotoxicity. This decrease in glutamate uptake is caused by the downregulation of glutamate transporter, GLT-1, in astrocytes, whose activity is dependent on Na<sup>+</sup>/K<sup>+</sup> activity that is regulated by A<sub>2A</sub>R (Matos et al., 2013). Interestingly, the genetic lowering of GLT-1 expression in AD mice (APP/PS1) causes an earlier onset of cognitive deficits (Mookherjee et al., 2011). The upregulation of A<sub>2A</sub>R in cultured astrocytes strongly modulates the transcriptome of these cells, affecting mainly genes related with neuroinflammation, angiogenesis and cell activation; some of the changes were reversed by a selective A<sub>2A</sub>R antagonist (Paiva et al., 2019). Although there is evidence suggesting that A<sub>2A</sub>R blockade restrains astrocyte reactivity (Hindley et al., 1994; Brambilla et al., 2003; Minghetti et al., 2007, see also Cunha, 2016), the pathophysiological impact of astrocytic A<sub>2A</sub>R upsurge in reactive astrocytes in conditions of brain disorders, in particular of AD, remains to be defined. It was described that A<sub>2A</sub>R in astrocytes regulate Ca<sup>2+</sup> efflux from the endoplasmic reticulum and glutamate release (Kanno and Nishizaki, 2012) and also ATP release (unpublished data from our group, Madeira D, poster #726, T05-063B, XIV European meeting on glial cells in health and disease) as well as GABA transport (Cristóvão-Ferreira et al., 2013), which support that astrocytic A<sub>2A</sub>R regulate the secretory capacity of these cells and, thus, impact on astrocyte-neuron communication. Therefore, taking in account the role of A<sub>2A</sub>R in controlling key astrocytic functions and the upregulation of A<sub>2A</sub>R in AD, it might be helpful to develop strategies, genetic or pharmacological, directed to tinker specifically with astrocytic A<sub>2A</sub>R to halt AD-associated cognitive decline.

**CONCLUSION AND FUTURE PERSPECTIVES**

Although it is known for over a century that astrocytes display substantial morphological alterations in AD brains,
neuronal damage has been considered the paramount pathological event causing cognitive decline. In recent years, this “neurocentric” view of AD has been changing, with the growing evidences that astrocytic morphological changes also reflect functional alterations with impact in AD pathology. Astrocytes are distributed throughout the brain in an optimal arrangement to establish chemical and physical interactions with neuronal synapses. Thus, changes in astrocyte morphology and function disturb synaptic contacts, function, and plasticity and, consequently, contribute to early cognitive deficits in AD (Figure 1). Understanding which astrocyte-neuronal signaling pathways are disrupted could lead to the development of more effective therapies as well as to the identification of novel biomarkers for synaptopathies, such as AD (Allen and Barres, 2009; Agostinho et al., 2020). Currently, a great research challenge has been the development of tools and strategies to detail the molecular pathways underlying the diverse functions of different astrocyte subpopulations, in particular of human astrocytes that are larger, more ramified and more heterogeneous than rodent astrocytes. Recent studies using refined labeling strategies based on astrocytic promoters, and intersectional fluorescence-activated cell sorting-based strategy, as well as single-cell RNA sequencing provided great advances in revealing distinct spatial distributions of distinct astrocyte populations, possessing distinct morphologies and physiologies (Morel et al., 2019; Batiuk et al., 2020). However, it remains to be explored how the morphology and function of different astrocytic subpopulations are influenced by local environment, mainly by signal instigators of disease as well as the molecular signals involved in astrocyte communication with other brain cells. Filling these gaps of knowledge will set the stage for tackling

FIGURE 1 | Astrocytes and A$_2$AR are active players in Alzheimer’s disease (AD). Adenosine A$_2$AR receptors (A$_2$AR) are upregulated in AD brain, namely in astrocytes. These glial cells are considered the third active element of the synapse, regulating synaptic plasticity, mainly long-term potentiation (LTP) and long-term depression (LTD) that are events mediated by AMPAR and NMDAR (receptors for glutamate). Astrocytes became reactive and dysfunctional in response to amyloid-$\beta$ peptide (A$\beta$) overproduction, derived from amyloid-$\beta$ precursor protein (A$\beta$PP) proteolytic cleavage. Astrocyte dysfunction negatively impacts on synaptic plasticity, the neurophysiological basis of memory. A$_2$AR regulate key functions of astrocytes, such as intracellular Ca$^{2+}$ levels [Ca$^{2+}$]$_i$, glutamate uptake by the transporter (GLT-1) and the release of ATP, and consequently regulate synaptic plasticity. Thus, A$_2$AR in astrocytes might be a therapeutical target to manage AD.
astrocytic functions as targets to delay the onset of synaptic and memory deficits in AD.

Adenosine exerts two parallel modulatory roles in the brain, acting as a homeostatic modulator and also as a neuromodulator at the synaptic level. Its effects are mediated by G protein-coupled receptors, being the subtypes A1R and A2AR the most abundant and studied. A2AR are considered to mediate excitatory effects and to be more involved in neurodegeneration, contrasting to A1R (reviewed in Lopes et al., 2020). Furthermore, increasing evidences show that A2AR levels are not only upregulated in neurons but also in astrocytes, in the brain of AD patients and of AD mouse models. Moreover, it was shown that the astrocytic A2AR upregulation contributes to memory loss in AD (Orr et al., 2015). These findings are relevant in view of the convergence of epidemiological and animal studies showing that caffeine intake is inversely correlated with memory deterioration in aging and AD, an effect mimicked by the selective A2AR blockade (Cunha, 2016). As discussed in this review, we are only beginning to unveil the role of adenosine signaling in the control of astrocyte-neuron communication. However, there are already a set of evidences that reinforces the interest of exploring the therapeutic potential of astrocytic A2AR. In the future, an ambitious challenge will be getting strategies, genetic or pharmacological, directed to A2AR in astrocytes that allow control of their functions to be introduced into clinical practice as novel drugs to AD.

AUTHOR CONTRIBUTIONS

All the authors participated in the writing of this manuscript.

FUNDING

This study was supported by La Caixa Foundation HR17-00523, Centro 2020 (CENTRO-01-0145-FEDER-000008: BrainHealth 2020 and CENTRO-01-0246-FEDER-000010) and FCT (PTDC/MED-NEU/31274/2017).

REFERENCES

Agostinho, P., Madeira, D., Dias, L., Simões, A. P., Cunha, R. A., and Canas, P. M. (2020). Purinergic signaling orchestrating neuron-glia communication. Pharmacol. Res. 162:105253. doi: 10.1016/j.phrs.2020.105253

Albasanz, J. L., Perez, S., Barrachina, M., Ferrer, I., and Martín, M. (2008). Up-regulation of adenosine receptors in the frontal cortex in Alzheimer's disease. Brain Pathol. 18, 211–219. doi: 10.1111/j.1750-3639.2007.00112.x

Allen, N. I., and Barres, B. A. (2009). Neuroscience: glia – more than just brain glue. Nature 457, 675–677. doi: 10.1038/457675a

Angulo, E., Casadó, V., Mallol, J., Canela, E. I., Viñals, F., Ferrer, I., et al. (2003). A2a adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 13, 440–451. doi: 10.1111/j.1750-3639.2003.00047.x

Araque, A., Parpura, V., Sanzgiri, R. P., and Hayden, P. G. (1999). Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 22, 208–215. doi: 10.1016/S0166-2236(98)01349-6

Arendash, G. W., Schlie, W., Rezai-Zadeh, K., Jackson, E. K., Zacharia, L. C., Cracchiolo, J. R., et al. (2006). Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain β-amyloid production. Neuroscience 142, 941–952. doi: 10.1016/j.neuroscience.2006.07.021

Augusto, E., Matos, M., Sávényi, J., El-Tayeb, A., Bynoe, M. S., Müller, C. E., et al. (2013). Ecto-5′-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions. J. Neurosci. 33, 11390–11399. doi: 10.1523/JNEUROSCI.5817-12.2013

Balducci, C., Tonini, R., Zianni, E., Nazzaro, C., Fiordaliso, F., Salio, M., et al. (2010). Cognitive deficits associated with alteration of synaptic plasticity precede plaque deposition in AβPP23 transgenic mice. J. Alzheimers Dis. 21, 1367–1381. doi: 10.3233/jad-2010-100675

Barreto, G. E., Gonzalez, J., Capani, F., and Morales, L. (2011). Neurodegenerative Diseases – Processes, Prevention, Protection and Monitoring. Rijeka: Intech, doi: 10.5772/1252

Batiuk, M. Y., Martyrosyan, A., Wahis, J., de Vin, F., Marmeche, C., Kusserow, C., et al. (2020). Identification of region-specific astrocyte subtypes at single cell resolution. Nat. Commun. 11:1220. doi: 10.1038/s41467-019-14198-8

Beach, T. G., and McGeer, E. G. (1988). Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer’s disease visual cortex. Brain Res. 463, 357–361. doi: 10.1016/00068993(88)90410-6

Beauquis, J., Vinuesa, A., Pomilio, C., Pavia, P., Galván, V., and Saravia, F. (2014). Neuronal and glial alterations, increased anxiety, and cognitive impairment before hippocampal amyloid deposition in PDAPP mice, model of Alzheimer’s disease. Hippocampus 24, 257–269. doi: 10.1002/hipo.22219

Blasko, I., Veerhuis, R., Stamper-Koutches, M., Saurwein-Teissl, M., Eikelenboom, P., and Grubeck-Loebenstein, B. (2000). Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes. Neurobiol. Dis. 7(6Pt B), 682–689. doi: 10.1006/nbdi.2000.0321

Boison, D., Chen, J.-F., and Fredholm, B. B. (2010). Adenosine signaling and function in glial cells. Cell Death Differ. 17, 1071–1082. doi: 10.1038/cdd.2009.131

Borota, D., Murray, E., Keelgh, C., Chang, A., Watabe, J. M., Ly, M., et al. (2014). Post-study caffeine administration enhances memory consolidation in humans. Nat. Neurosci. 17, 201–203. doi: 10.1038/nn.3623

Brambilla, R., Cottini, L., Fumagalli, M., Cerutzi, S., and Abbracchio, M. P. (2003). Blockade of A2A, adenosine receptors prevents basic fibroblast growth factor-induced reactive astroglia formation in rat striatal primary astrocytes. Glia 43, 190–194. doi: 10.1002/glia.10243

Brisevac, D., Adzic, M., Laketa, D., Parabucki, A., Milosevic, M., Lavrnja, I., et al. (2015). Extracellular ATP selectively upregulates ecto-nucleoside triphosphate diphosphohydrolase 2 and ecto-5′-nucleotidase by rat cortical astrocytes In Vitro. J. Mol. Neurosci. 57, 452–462. doi: 10.1007/s12031-015-0601-y

Canas, P. M., Cunha, R. A., and Agostinho, P. (2018). “Adenosine receptors in Alzheimer’s disease,” in The Adenosine Receptors. The Receptors, Vol. 34, eds P. Borea, K. Varani, S. Gessi, S. Merighi, and F. Vincenzi (Cham: Humana Press), doi: 10.1007/978-3-319-90088-3_11

Canas, P. M., Porciúncula, L. O., Cunha, G. M. A., Silva, C. G., Machado, N. J., Oliveira, J. M. A., et al. (2009). Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by β-amyloid peptides via p38 mitogen-activated protein kinase pathway. J. Neurosci. 29, 14741–14751. doi: 10.1523/JNEUROSCI.3728-09.2009

Cao, C., Cirrito, J. R., Lin, X., Wang, L., Verges, D. K., Dickson, A., et al. (2009). Caffeine suppresses amyloid-β levels in plasma and brain of Alzheimer’s disease transgenic mice. J. Alzheimers Dis. 17, 681–697. doi: 10.3233/JAD-2009-1071

Carman, A. J., Mills, J. H., Krenz, A., Kim, D. G., and Bynoe, M. S. (2011). Adenosine receptor signaling modulates permeability of the blood-brain barrier. J. Neurosci. 31, 13272–13280. doi: 10.1523/JNEUROSCI.3337-11.2011

Carmo, M., Gonçalves, F. Q., Canas, P. M., Oses, J.-P., Fernandes, F. D., Duarte, F. V., et al. (2019). Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A2A receptor over-activation in a rat model of Parkinson’s disease. Br. Pharmacol. 176, 3666–3680. doi: 10.1111/bph.14771

Cervetto, C., Venturini, A., Passalacqua, M., Guidolin, D., Genedani, S., Fuxe, K., et al. (2017). A2A-D2 receptor-receptor interaction modulates gliotransmitter
release from striatal astrocyte processes. J. Neurochem. 140, 268–279. doi: 10.1111/j.1365-2468.2015.13885

Ceyzériat, K., Haim, L. B., Denizot, A., Pommier, D., Matos, M., Guilleaumou, O., et al. (2018). Modulation of astrocytic reactive immunoactivation in mouse models of Alzheimer’s disease. Acta Neuropathol. Commun. 6:104. doi: 10.1186/s40478-018-0606-1

Chen, J. F. (2014). Adenosine receptor control of cognition in normal and disease. Front. Physiol. 5, 289. doi: 10.3389/fphys.2014.00289

Fowler, J. S., Volkow, N. D., Wang, G. J., Logan, J., Pappas, N., Shea, et al. (2009). Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol. Aging 30, 1398–1412. doi: 10.1016/j.neurobiolaging.2009.02.002

Fredholm, B. B., Chen, J.-F., Cunha, R. A., Svwnningsson, P., and Vaugeois, J.-M. (2005). Adenosine and brain function. Int. Rev. Neurobiol. 63, 191–270. doi: 10.1016/S0077-4742(05)80037-3

Frost, G. R., and Li, Y. M. (2017). The role of astrocytes in amyloid production and Alzheimer’s disease. Open Biol. 7:170228. doi: 10.1098/rsob.170228

Fukumitsu, N., Ishii, K., Kimura, Y., Oda, K., Hashimoto, M., Suzuki, M., et al. (2008). Adenosine A1 receptors using 8-dicyclopropylmethyl-[11C]methyl-3- propylxanthine PET in Alzheimer’s disease. Amn. Nuc. Med. 22, 841–847. doi: 10.1121/1.41198-008-0185-5

Gallardo, G., and Holtzman, D. M. (2019). Amyloid-β and tau at the crossroads of Alzheimer’s disease. Adv. Exp. Med. Biol. 1184, 187–203. doi: 10.1007/978-3-239-58-8_16

Garwood, C. J., Ratcliffe, L. E., Simpson, J. E., Health, P. R., Ince, P. G., and Wharton, S. B. (2017). Review: astrocytes in Alzheimer’s disease and other age-associated dementias: a supporting player with central role. Neurophatol. Appl. Neurobiol. 43, 281–298. doi: 10.1111/jan.12338

Genoud, C., Quairiaux, C., Steiner, P., Hirling, H., Welker, E., and Knott, G. W. (2006). Plasticity of astrocytic coverage and glutamate transporter expression in adult mouse cortex. PLoS Biol. 4:e343. doi: 10.1371/journal.pbio.0040343

Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., and Cunha, R. A. (2011). Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Brain 142, 3323–3324. doi: 10.1093/brain/awr335

Cunha, R. A., and Agostinho, P. M. (2010). Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J. Alzheimers Dis. 20(suppl. 1), 595–516. doi: 10.3233/JAD-2010-1408

Cunha, R. A., Johansson, B., Fredholm, B. B., Ribeiro, J. A., and Sebastião, A. M. (1995). Adenosine A2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neurosci. Lett. 196, 41–44. doi: 10.1016/0304-3940(95)01833-1

Dall’igna, O. P., Fett, P., Gomes, M. W. S., Souza, D. O., Cunha, R. A., and Lara, D. R. (2007). Caffeine and adenosine A2A receptor antagonists prevent β-amylloid (25-35)-induced cognitive deficits in mice. Exp. Neurol. 203, 241–245. doi: 10.1016/j.expneurol.2006.08.008

Daré, E., Schulte, G., Karovic, O., Hammarberg, C., and Fredholm, B. B. (2007). Modulation of glial cell functions by adenosine receptors. Physiol. Behav. 92, 15–20. doi: 10.1016/j.physbeh.2007.05.031

Diogène, M. J., Assafel-Lopes, N., Pinto-Duarte, A., Ribeiro, J. A., and Sebastiao, A. M. (2007). Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors. Hippocampus 17, 577–585. doi: 10.1002/hipo.20294

Escarint, C., Galea, E., Lakatos, A., O’Callaghan, J. P., Petzold, G. C., Serrano-Pozo, A., et al. (2021). Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 24, 312–325. doi: 10.1038/s41593-020-00783-4

Eskelin, M. H., Ngandu, T., Tuomilehto, J., Soininen, H., and Kivipelto, M. (2009). Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J. Alzheimers Dis. 16, 85–91. doi: 10.3233/JAD-2009-0920

Espinosa, J., Rocha, A., Nunes, F., Costa, M. S., Schein, V., Kralaucas, V., et al. (2013). Caffeine consumption prevents memory impairment, neuronal damage, and adenosine A2A receptor upregulation in the hippocampus of a rat model of sporadic dementia. J. Alzheimers Dis. 34, 509–518. doi: 10.3233/JAD-111982

Fowler, J. S., Volkow, N. D., Wang, G. J., Logan, J., Pappas, N., Shea, C., et al. (1997). Age-related increases in brain monoamineoxidase B in living healthy human subjects. Neurobiol. Aging 18, 431–435. doi: 10.1016/S0197-4580(97)00017-7

Franco, R., and Navarro, G. (2018). Adenosine A2A receptor antagonists in neurodegenerative diseases: huge potential and huge challenges. Front. Psychiatry 9:68. doi: 10.3389/fspst.2018.00068
hippocampal slice cultures. Cell Calcium 49, 249–258. doi: 10.1016/j.ceca.2011.02.009
Ke, R. H., Xiong, J., Liu, Y., and Ye, Z. R. (2009). Adenosine A2A receptor induced
gliaosis via Akt/FOXKappaB pathway in vitro. Neurosci. Res. 65, 280–285. doi: 10.1016/j.neures.2009.08.002
Kovacs, G. G. (2020). Astroglia and tau: new perspectives. Front. Aging Neurosci. 12, 96. doi: 10.3389/fnagi.2020.00096
Kuchibhotla, K. V., Lattarulo, C. R., Hyman, B. T., and Bacsai, B. J. (2009). Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer's
data. Science 323, 1211–1215. doi: 10.1126/science.1169096
Kulijewicz-Nawrot, M., Vehrkratsky, A., Chvátal, A., Sykóva, E., and Rodríguez, J. J. (2012). Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a
tripe transgenic mouse model of Alzheimer's disease. J. Anat. 221, 252–262. doi: 10.1111/j.1469-7588.2012.01536.x
Laurent, C., Burnouf, S., Ferrry, B., Batalha, V. L., Coelho, J. E., Baqi, Y., et al. (2016). A3A adenosine receptor deletion is protective in a mouse model of Tauopathy.
Mol. Psychiatry 21, 149. doi: 10.1038/mp.2015.115
Laurent, C., Eddarkaoui, S., Derisbourg, M., Leboucher, A., Demeyster, D., Carrier, S., et al. (2014). Beneficial effects of caffeine in a transgenic model of Alzheimer's
disease-like tau pathology. Neurobiol. Aging 35, 2079–2090. doi: 10.1016/j.neurobiolaging.2014.03.027
Lemos, C., Pinheiro, B. S., Beleza, R. O., Marques, J. M., Rodrigues, R. R., Cunha, R. A., et al. (2015). Adenosine A2B receptor activation stimulates glucose uptake in the
mouse forebrain. Purinergic Signal. 11, 561–569. doi: 10.1007/s11302-015-9474-3
Li, P., Rial, D., Canas, P. M., Yoo, J. H., Li, W., Zhou, X., et al. (2015). Optogenetic
activation of intracellular adenosine A3A receptor signaling in the hippocampus is
efficient to trigger CREB phosphorylation and impaired memory. Mol. Psychiatry 20:1481. doi: 10.1038/mp.2015.43
Lopes, C. R., Lourençou, V. S., Tomé, A. R., Cunha, R. A., and Canas, P. M. (2020). Use of knockout mice to explore CNS effects of adenosine. Biochem. Pharmacol.
187:114367. doi: 10.1016/j.bjcp.2020.114367
Lovatt, D., Xu, Q., Liu, W., Takano, T., Smith, N. A., Schnermann, J., et al. (2012).
Neuronal adenosine release, and not astrocytic ATP release, mediates feedback
inhibition of excitatory activity. Proc. Natl. Acad. Sci. U.S.A. 109, 6265–6270. doi: 10.1073/pnas.1209971109
Maia, L., and de Mendonça, A. (2002). Does caffeine intake protect from Alzheimer's
disease? Neuropsychobiology 46, 239–243. doi: 10.1038/nn.3930
Overmeyer, M., Kraszpuszki, M., Helisalmi, S., Soininen, H., and Alafuzoff, I. (2000). DNA
gmentation, glissos and histological hallmarks of Alzheimer's disease. Acta Neuropathol.
100, 681–687. doi: 10.1007/s004010000228
Pagnussat, N., Almeida, A. S., Marques, D. M., Nunes, F., Chenet, G. C., Botton, P. H., et al. (2015). Adenosine A2A receptors are necessary and sufficient to
tigger memory impairment in adult mice. Br. J. Pharmacol. 172, 3831–3845. doi: 10.1111/bph.13180
Paiva, I., Carvalho, K., Santos, P., Cellai, L., Pavlou, M. A. S., Jain, G., et al. (2019).
Beneficial effects of caffeine in a transgenic model of Alzheimer's disease.
Front. Aging Neurosci. 12:96. doi: 10.3389/fnagi.2020.00096
Parpura, V., Basarsky, T. A., Liu, F., Jeftinija, K., Jeftinija, S., and Haydon, P. G. (1994).
Glutamate-mediated astrocyte-neuron signaling. Nature 369, 744–747. doi: 10.1038/369744a0
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J.-Y., et al. (2005). Synaptic astroglial purinergic signaling coordinates synaptic networks. Science
310, 113–116. doi: 10.1126/science.1116916
Rebola, N., Canas, P. M., Oliveira, C. R., and Cunha, R. A. (2005). Different synaptic and
subsynaptic localization of adenosine A2A receptors in the hippocampus and
striatum of the rat. Neuroscience 123, 893–903. doi: 10.1016/j.neuroscience.2005.01.014
Rebola, N., Lujan, R., Cunha, R. A., and Mulle, C. (2008). Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal
 mossy fiber synapses. Neuron 57, 121–134. doi: 10.1016/j.neuron.2007.11.023
Rebola, N., Pinheiro, P. C., Oliveira, C. R., Malva, J. O., and Cunha, R. A. (2003). Subcellular localization of adenosine A1 receptors in nerve terminals and
 synapses of the rat hippocampus. Brain Res. 987, 49–58. doi: 10.1016/s0006-8993(03)0247-5
Richetin, K., Steullet, P., Pachoud, M., Perbet, R., Parietti, E., Maheswaran, M., et al.
(2003). Mechanisms of A1 receptor induced transcriptional deregulation in astrocytes: an in vitro study. Glia 37, 2329–2342. doi: 10.1002/glia.10168
Rodríguez, J. J., Olabarria, M., Nombela, T., Hada, H., Kanno, T., Tozaki, H., et al. (2002).
A new neuromodulatory pathway with a glial contribution mediated via A2A
adenosine receptors. Glia 39, 133–147. doi: 10.1002/glia.10100
Rors, A. G., Hisao, E. C., Wang, M. M., Ho, K., Kim, D. H., Wang, X., et al. (2015).
Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory.
Nat. Neurosci. 18, 423–434. doi: 10.1038/nn.3930
Sastre, M., and Sastre, M. (2016). Mechanisms of A2A receptors in the hippocampus
and Degradation by Glial Cells. Front. Aging Neurosci. 8:160.
Rodríguez, J. J., Yeh, C.-Y., Terzieva, S., Olabarria, M., Kulíjewicz-Nawrot, M., and Verkhratsky, A. (2014). Complex and region-specific changes in astroglial markers in the aging brain. *Neurobiol. Aging* 35, 15–23. doi: 10.1016/j.neurobiolaging.2013.07.002

Rodríguez-Arellano, J. J., Parpura, V., Zorec, R., and Verkhratsky, A. (2016). Astrocytes in physiological aging and Alzheimer's disease. *Neuroscience* 323, 170–182. doi: 10.1016/j.neuroscience.2015.01.007

Samakhsivili, S., İnánez, C., Simó, C., Gil-Bea, F. J., Winbled, B., Cedazo-Minguez, A., et al. (2011). Analysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease. *Electrophoresis* 32, 2757–2764. doi: 10.1002/elps.201100139

Sastre, M., Dewachter, I., Landreth, G. E., Willson, T. M., Klockgether, T., van Leuven, F., et al. (2003). Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β-secretase. *J. Neurosci.* 23, 9796–9804. doi: 10.1523/JNEUROSCI.23–30–09796.2003

Scimemi, A., Meabon, J. S., Woltjer, R. L., Sullivan, J. M., Diamond, J. S., and Sullivan, J. M., Diamond, J. S., and Cook, D. G. (2013). Amyloid-β1–42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. *J. Neurosci.* 33, 5312–5318. doi: 10.1523/JNEUROSCI.5274–12.2013

Selkoe, D. J., and Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. *EMBO Mol. Med.* 8, 595–608. doi: 10.15252/emmm.201606210

Serrano-Pozo, A., Frosch, M. P., Masliah, E., and Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. *Cold Spring Harb. Perspect. Med.* 3:a006189. doi: 10.1186/1742-2094-8-150

Silva, A. C., Lemos, C., Gonçalves, F. Q., Plássiova, A. V., Machado, N. J., Silva, H. B., et al. (2018). Blockade of adenosine A₂A receptors recovers early deficits of memory and plasticity in the triple transgenic mouse model of Alzheimer's disease. *Neurobiol. Dis.* 117, 72–81. doi: 10.1016/j.nbd.2018.05.024

Takahashi, R. N., Pamplona, F. A., and Prediger, R. D. (2008). Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. *Front. Biosci.* 13:2614–2632. doi: 10.2741/2870

Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M. W., Okamoto, S., et al. (2013). Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. *Proc. Natl. Acad. Sci. U.S.A.* 110, E2518–E2527. doi: 10.1073/pnas.1306832110

Temido-Ferreira, M., Ferreira, D. G., Batalha, V. L., Marques-Morgado, I., Coelho, J. E., Pereira, P., et al. (2020). Age-related shift in LTD is dependent on neuronal adenosine A₂A receptors interplay with mGluR5 and NMDA receptors. *Mol. Psychiatry* 25, 1876–1900. doi: 10.1038/s41380-018-0110-9

Verkhratsky, A., Rodrigues, J. J., Pivoriunas, A., Zorec, R., and Semyanov, A. (2019). Astroglial atrophy in Alzheimer's disease. *Pflügers Arch.* 471, 1247–1261. doi: 10.1007/s00424-019-02310-2

Verkhratsky, A., Zorec, R., Rodríguez, J. J., and Parpura, V. (2016). Astroglia dynamics in ageing and Alzheimer's disease. *Curr. Opin. Pharmacol.* 26, 74–79. doi: 10.1016/j.coph.2015.09.011

Viana da Silva, S., Haberl, M. G., Zhang, P., Bethge, P., Lemos, C., Gonçalves, N., et al. (2016). Early synaptic deficits in the APP/PS1 mouse model of Alzheimer's disease involve neuronal adenosine A₂A receptors. *Nat. Commun.* 7:19115. doi: 10.1038/ncomms1915

Wishart, T. M., Parson, S. H., and Gillingwater, T. H. (2006). Synthetic vulnerability in neurodegenerative disease. *J. Neuropathol. Exp. Neurol.* 65, 733–739. doi: 10.1097/01.jnep.0000228202.35163.c4

Wu, Z., Guo, Z., Gearing, M., and Chen, G. (2014). Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model. *Nat. Commun.* 5:4159. doi: 10.1038/ncomms5159

Wys-Coray, T., Loike, J. D., Brisonne, T. C., Lu, E., Anankov, R., Yan, F., et al. (2003). Adult mouse astrocytes degrade amyloid-β in vitro and in situ. *Nat. Med.* 9, 453–457. doi: 10.1038/nm838

Yeh, C.-Y., Vadhwana, B., Verkhratsky, A., and Rodriguez, J. J. (2011). Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease. *ASN Neuro* 3, 271–279. doi: 10.1042/AN20110025

Yoshie, Y., Kimura, T., Yamashita, S., Furudate, H., Mizaroki, T., Murayama, M., et al. (2008). GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. *PLoS One* 3:e3029. doi: 10.1371/journal.pone.0003029

Zhao, J., O’Connor, T., and Vassar, R. (2011). The contribution of activated astrocytes to Aβ production: implications for Alzheimer’s disease pathogenesis. *J. Neuroinflammation* 8:150. doi: 10.1186/1742-2094-8-150

Zumkehr, J., Rodríguez-Ortiz, C. J., Cheng, D., Kieu, Z., Wai, T., Hawkins, C., et al. (2015). Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease. *Neurobiol. Aging* 36, 2260–2271. doi: 10.1016/j.neurobiolaging.2015.04.000

Conflict of Interest: RC is a scientific advisor of the Institute for Scientific Information on Coffee (ISIC). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Lopes, Canha and Agostinho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.